Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing

por Chang, Ih, Muralidharan, Kumar Kandadi, Campbell, Nolan, Ho, Pei‐Ran
Publicado 2020

Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay

por Campagnolo, Denise, Dong, Qunming, Lee, Lily, Ho, Pei-Ran, Amarante, Diogo, Koendgen, Harold
Publicado 2016

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

por Butzkueven, Helmut, Licata, Stephanie, Jeffery, Douglas, Arnold, Douglas L, Filippi, Massimo, Geurts, Jeroen JG, Santra, Sourav, Campbell, Nolan, Ho, Pei-Ran
Publicado 2020

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

por Butzkueven, Helmut, Kappos, Ludwig, Wiendl, Heinz, Trojano, Maria, Spelman, Tim, Chang, Ih, Kasliwal, Rachna, Jaitly, Seema, Campbell, Nolan, Ho, Pei-Ran, Licata, Stephanie
Publicado 2020

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Obser...

por Butzkueven, Helmut, Kappos, Ludwig, Spelman, Tim, Trojano, Maria, Wiendl, Heinz, Su, Ray, Liao, Shirley, Hyde, Robert, Licata, Stephanie, Ho, Pei-Ran, Campbell, Nolan
Publicado 2021

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

por Brown, Jacques P, Roux, Christian, Törring, Ove, Ho, Pei-Ran, Beck Jensen, Jens-Erik, Gilchrist, Nigel, Recknor, Christopher, Austin, Matt, Wang, Andrea, Grauer, Andreas, Wagman, Rachel B
Publicado 2013

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

por Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan
Publicado 2019

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

por Plavina, Tatiana, Muralidharan, Kumar Kandadi, Kuesters, Geoffrey, Mikol, Daniel, Evans, Karleyton, Subramanyam, Meena, Nestorov, Ivan, Chen, Yi, Dong, Qunming, Ho, Pei-Ran, Amarante, Diogo, Adams, Alison, De Sèze, Jerome, Fox, Robert, Gold, Ralf, Jeffery, Douglas, Kappos, Ludwig, Montalban, Xavier, Weinstock-Guttman, Bianca, Hartung, Hans-Peter, Cree, Bruce A.C.
Publicado 2017